Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder: a Multicenter Retrospective Study of Selected Follow-up Cohort

Study Objective: To evaluate the treatment effectiveness and safety by analyzing prescription patterns in a routine clinical practice setting and observing changes in clinical indicators (weight, BMI, HAM-D, CGI-S, CGI-I) among patients prescribed Lurasidone for the treatment of bipolar disorder. Study Design: Retrospective, Multi-center, Investigator-Initiated Observational Study.

Inclusion Criteria: 1. Adults aged 18 to 65 years 2. Confirmed diagnosis of bipolar disorder 3. Minimum 8-week stable treatment on atypical antipsychotics (Aripiprazole, Olanzapine, Quetiapine) followed by a switch to Lurasidone due to metabolic side effects (weight gain). 4. Completed 16-week follow-up post-switch Exclusion Criteria: 1. Pregnant or lactating women 2. Subjects for whom administration of lurasidone is contraindicated according to the approved labeling 3. Subjects who discontinued lurasidone or switched to another medication within 8 weeks of the initial switch to lurasidone 4. Subjects for whom data on body weight, height, HAM-D, CGI-S, or CGI-I were not collected at least once across all visits 5. Subjects judged by the investigator to be ineligible for participation in the study for other reasons